Who holds the patent for Lanreotide?
Introduction to Lanreotide
Overview and Uses
Lanreotide is a synthetic polypeptide analogue designed to mimic the physiological behavior of the natural hormone somatostatin. It is primarily used in clinical settings to suppress the secretion of various hormones, particularly growth hormone, insulin, and gastrointestinal peptides. Its therapeutic applications have been well established in the treatment of acromegaly—a condition characterized by excessive growth hormone production—and neuroendocrine tumors that often result in hormonal hypersecretion. In addition, lanreotide is formulated in a long-acting release form which advantages patients by providing prolonged therapeutic effects with less frequent dosing, thereby improving compliance and quality of life. This formulation is especially beneficial for chronic administration and has led to significant clinical advancements in managing hormonal disorders.
Clinical studies and regulatory approvals further cement its role as a first-line treatment option in disruptive endocrine conditions, owing to its capacity to provide both symptom control and potential antitumor effects. As such, lanreotide stands as a vital component within the landscape of somatostatin analog therapies, bridging the gap between acute intervention and chronic disease management.
Mechanism of Action
Lanreotide’s mechanism of action is based on its potent affinity to somatostatin receptors, primarily SSTR2 and SSTR5, expressed on the surface of endocrine cells. Upon binding to these receptors, lanreotide exerts an inhibitory effect on hormone secretion. Specifically, it suppresses the release of growth hormone by acting on the anterior pituitary as well as modulating the secretion of gastrointestinal hormones such as insulin, glucagon, gastrin, and cholecystokinin. This multi-receptor targeting therefore not only initiates direct receptor-mediated inhibition of hormone release, but also indirectly reduces the overstimulation seen in various tumors.
The extended half-life and sustained-release formulation of lanreotide enable it to maintain therapeutic concentrations over prolonged periods, thereby reducing the frequency of administration to, for instance, once a month or even extending into bimonthly dosing under certain approved circumstances. Furthermore, by offering improved pharmacokinetic profiles compared to natural somatostatin—whose half-life is measured in minutes—lanreotide represents an evolution in peptide-based drug design that combines efficacy with enhanced patient convenience.
Patent Landscape of Lanreotide
Key Patent Holders
The global patent portfolio covering lanreotide is pivotal in maintaining its market exclusivity and ensuring continuous investment in research and development. Detailed information derived from patent documentation in the synapse database indicates that the current primary patent holder for lanreotide is represented by the entity “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ.” This assignee is listed as the current holder in multiple key patents related to the sustained-release pharmaceutical compositions of lanreotide. For example, the patent documented under citation “Method for manufacturing a pharmaceutical composition for sustained release of somatostatin analogues” as well as the patent under citation “PHARMACEUTICAL COMPOSITION OF SUSTAINED-RELEASE PEPTIDE AND METHOD FOR MANUFACTURE THEREOF” both clearly show that the current assignee is “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ.”
This information is corroborated by the subsequent assignment details in these patents, making it evident that the strategic intellectual property for lanreotide, particularly in its sustained-release formulations, rests primarily with this company. Although the patents are commonly subject to modifications in different jurisdictions, the global trend points to a unified control by this assignee. This approach is a common strategy among biopharmaceutical companies to enforce market exclusivity and safeguard intellectual property assets.
Beyond the primary patents, various related composition and manufacturing method patents exist that further consolidate the protection around lanreotide-based treatments. Nevertheless, “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ” emerges as the central figure in the patent landscape for lanreotide, reflecting its significant influence over the commercial and clinical deployment of the drug.
Patent Expiry and Legal Status
Patents for pharmaceutical compositions are critical assets that determine the period during which a drug can be exclusively marketed. The key patents for lanreotide, especially those related to innovative sustained-release compositions, have specific filing, publication, and expiry dates which are integral to understanding the drug’s lifecycle and market exclusivity timeline. For instance, the patent under citation with patent number JP4162381B2 has an application date of 19990322 and a publication date of 20081008, with an expiration date noted as 20230218. This expiration date sets a finite period during which the patent holder retains exclusive rights, after which the formulation could potentially face generic competition.
In another related patent, citation with the patent JP6029472B2 is indicative of a comprehensive method for manufacturing a sustained-release formulation of lanreotide acetate. Although the exact expiration details in the available summary might present a different date format or be subject to renewal terms, it is clear that these patents are vital in maintaining market exclusivity well into the future.
The legal status, bolstered by robust documentation in the synapse system, shows that these patents are currently maintained and enforced by the assignee, reducing the opportunity for competitors to introduce similar formulations into the market without licensing agreements or technology transfers. The potential for patent term extensions under regulatory provisions such as the Hatch-Waxman Act or equivalent measures in non-U.S. jurisdictions means that the effective market protection for lanreotide could be prolonged beyond the nominal expiry dates, safeguarding continued innovation and returns on investment.
Implications of Patent Ownership
Market Impact
The concentration of patent ownership in the hands of “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ” yields several significant market implications. First and foremost, the exclusivity granted by these patents ensures that the market for lanreotide is predominantly under the control of a single entity, which can set pricing strategies, control supply, and invest in further research and development without immediate generic competition. This level of control typically allows the patent holder to command premium pricing, especially in markets where alternative treatments may not offer the same level of efficacy or convenience.
From a regulatory and healthcare system perspective, maintaining a period of exclusivity is essential not only to recoup R&D investments but also to fund post-marketing surveillance and additional clinical trials aimed at expanding the indications for the drug. As such, the robust patent portfolio contributes to the stability and continued advancement of lanreotide-based therapies. This exclusivity continues well beyond the early launch phase of the drug, allowing the patent holder to build substantial market share and potentially drive forward integrated care secondary markets—for instance, specialized delivery systems or combination therapies.
Moreover, the protection offered by these patents has implications for investor confidence. Firms with robust patent portfolios are generally viewed as lower risk for future returns in the biopharmaceutical sector, particularly when patents cover both the compound itself and innovative methods of manufacture, such as sustained-release formulations. This market impact extends to competitive dynamics, where striking a balance between innovation and competition is critical for long-term sustainability in the biopharmaceutical industry.
Competitive Landscape
The patent ownership landscape for lanreotide directly influences competitive strategies among other pharmaceutical companies. Given that “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ” is the primary patent holder, competitors seeking to develop biosimilars or generic versions are faced with significant legal and regulatory hurdles. This scenario compels alternative companies to either focus on non-infringing design around strategies or enter into licensing agreements that allow them to incorporate aspects of the patented technology.
In the broader biopeptide market, where multiple somatostatin analogues are available such as octreotide and pasireotide, the exclusivity provided by these patents offers a competitive advantage to lanreotide in specific segments of acromegaly treatment and neuroendocrine tumor management. The clinical superiority of lanreotide’s formulation, particularly with its deep subcutaneous injection method, further consolidates its place in the pharmaceutical market. This exclusivity can disrupt the competitive forces by limiting the number of concomitant rivals, thus giving the patent holder the ability to steer market trends and even influence pricing strategies across regions.
Additionally, patent strategies and the legal frameworks associated with them play a crucial role in the competitive dynamics of the sector. Comprehensive patent protection, as evidenced by the portfolio for lanreotide, tends to deter small and mid-sized companies from entering the market without fully addressing potential infringement issues. This legal barrier not only prevents the erosion of the patent holder’s market share but also fosters an environment where extensive R&D investments continue to be made into improving existing therapeutic options as well as exploring potential new indications for the drug.
Future Developments
Upcoming Patents
While the current portfolio strongly centers around the core formulations and methods of sustained release for lanreotide, the rapidly evolving nature of biopharmaceutical research suggests that additional improvements and novel formulations may soon be targeted for patent protection. Research and development activities in the field of peptide therapeutics are continuously aiming to enhance drug efficacy, reduce adverse side effects, and improve administration convenience. This means that potential upcoming patents could address these areas by introducing formulations with improved bioavailability, novel delivery devices, or combinations with other therapeutic agents aimed at synergistic effects.
The patent term and breadth of protection provided by the existing patents give a framework for upcoming filings. For instance, new patents might focus on methods that extend the duration of action even further, modify the peptide structure for improved receptor binding, or combine lanreotide with other treatment modalities in a single formulation. Such advancements could be crucial in expanding the use-case scenarios of lanreotide beyond its traditional indications and improving overall therapeutic outcomes.
It is also likely that research efforts in different jurisdictions will yield a variety of patent filings. Given the global nature of the pharmaceutical market, future patents could target not only the United States but also Europe, Japan, and other significant markets, thus ensuring a synchronized worldwide patent protection strategy for improved versions of lanreotide. These developments, if successfully patented, will continue to reinforce the market dominance of the current patent holder while also providing a buffer period against generic competition through extended market exclusivity.
Research and Development
Continuous R&D is an indispensable element in the lifecycle of any biopharmaceutical product, and lanreotide is no exception. The firm holding the patent, “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ”, is anticipated to leverage its strong intellectual property position to drive further innovation. Research efforts are likely concentrated on optimizing the pharmacokinetic properties and expanding the therapeutic indications of lanreotide. Potential areas of focus include combination therapies that pair lanreotide with other agents to enhance antitumor effects or improve the management of endocrine disorders.
Moreover, the sustained-release technology implemented in lanreotide formulations is subject to continuous improvement through advances in drug delivery systems. Novel methods that reduce manufacturing costs or enhance patient convenience (such as self-administration devices) are highly desirable in the competitive pharmaceutical landscape. This R&D trajectory is supported by an environment rich in complementary patents that together create a robust barrier to entry for potential competitors.
Collaborations between academic institutions, research hospitals, and the patent-holding company are also anticipated to contribute significantly to these R&D efforts. Such partnerships may yield breakthrough clinical data or novel mechanisms by which the composed peptide can be more effectively targeted to specific tissues. This therapeutic innovation, in turn, reinforces the intellectual property portfolio and further delays potential generic competition.
Furthermore, regulatory strategies will continue to play a pivotal role in shaping the R&D directions for lanreotide. Continuous dialogue with regulatory bodies ensures that new patents are not only innovative but also align with clinical efficacy and safety standards, thereby supporting the robustness of the drug’s market position. Ultimately, sustained research and subsequent patent filings will further consolidate the central market role of lanreotide and maintain its long-term viability in a competitive therapeutic arena.
Conclusion
In summary, the patent landscape for lanreotide is dominated by the pharmaceutical entity “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ” as evidenced by key patents. These patents cover critical aspects of the sustained-release compositions and manufacturing methods that underlie the clinical success of lanreotide as a somatostatin analogue. The detailed patent information, including specific filing, publication, and expiry dates, reflects a well-organized intellectual property strategy employed by the patent holder, which is integral to maintaining the drug’s market exclusivity and competitive positioning.
The exclusive patent ownership has far-reaching implications in terms of market impact and competitive dynamics. By securing robust patent protection, the patent holder can deter generic competition, maintain premium pricing, and continue to invest in further innovation. The strategic control over these intellectual property rights facilitates a strong market presence, positive investment sentiment, and a stable revenue stream that can be reinvested into future research and development.
Looking toward the future, ongoing R&D efforts and potential upcoming patents are expected to further enhance the existing formulation and possibly extend the therapeutic applications of lanreotide. This forward-looking approach is anticipated to not only prolong market exclusivity through patent term extensions and improved formulations but also to drive additional clinical value through novel delivery systems and combination therapies.
Overall, the comprehensive patent portfolio centered on lanreotide, spearheaded by “イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ,” plays a critical role in ensuring that the innovative therapeutic benefits of lanreotide remain protected and commercially viable. This integrated strategy of patent ownership, market exclusivity, and continuous innovation stands as a robust model for sustaining competitive advantage in the dynamic biopharmaceutical industry.
For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！
